Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?

Publication ,  Journal Article
Curzen, N; Gurbel, PA; Myat, A; Bhatt, DL; Redwood, SR
Published in: Lancet
August 17, 2013

Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the central role of platelets in initiation and orchestration of this process has become clear. Key components of STEMI include formation of occlusive thrombus, mediation and ultimately amplification of the local vascular inflammatory response resulting in increased vasoreactivity, oedema formation, and microvascular obstruction. Activation, degranulation, and aggregation of platelets are the platforms from which these components develop. Therefore, prompt, potent, and predictable antithrombotic therapy is needed to optimise clinical outcomes after primary percutaneous coronary intervention. We review present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the optimum combination when primary percutaneous coronary intervention is used as the mode of revascularisation in patients with STEMI.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

August 17, 2013

Volume

382

Issue

9892

Start / End Page

633 / 643

Location

England

Related Subject Headings

  • Thrombolytic Therapy
  • Platelet Membrane Glycoprotein IIb
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Reperfusion
  • Myocardial Infarction
  • Integrin beta3
  • Infusions, Parenteral
  • Humans
  • General & Internal Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Curzen, N., Gurbel, P. A., Myat, A., Bhatt, D. L., & Redwood, S. R. (2013). What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet, 382(9892), 633–643. https://doi.org/10.1016/S0140-6736(13)61453-1
Curzen, Nicholas, Paul A. Gurbel, Aung Myat, Deepak L. Bhatt, and Simon R. Redwood. “What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?Lancet 382, no. 9892 (August 17, 2013): 633–43. https://doi.org/10.1016/S0140-6736(13)61453-1.
Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet. 2013 Aug 17;382(9892):633–43.
Curzen, Nicholas, et al. “What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?Lancet, vol. 382, no. 9892, Aug. 2013, pp. 633–43. Pubmed, doi:10.1016/S0140-6736(13)61453-1.
Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet. 2013 Aug 17;382(9892):633–643.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

August 17, 2013

Volume

382

Issue

9892

Start / End Page

633 / 643

Location

England

Related Subject Headings

  • Thrombolytic Therapy
  • Platelet Membrane Glycoprotein IIb
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Reperfusion
  • Myocardial Infarction
  • Integrin beta3
  • Infusions, Parenteral
  • Humans
  • General & Internal Medicine